medRxiv preprint doi: https://doi.org/10.1101/2021.12.10.21267607; this version posted December 13, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Article	1
High correlation between binding IgG (anti-RBD/S)	2
and neutralizing antibodies against SARS-CoV-2 six	3
months after vaccination	4
Raquel Guiomar 1.7,*, Ana João Santos 2,7,*, Aryse Martins Melo 1.7, Inês Costa 1, Rita Matos 5, Ana Paula Rodrigues 2, Irina Kislaya 2, Anabela Santos Silva 3 , Carla Roque 6, Carla Silva 3, Joaquim Aguiar 3, Fátima Graça 3, Antônio Silva Graça 4, Ausenda Machado 2	5 6 7
¹ National Reference Laboratory for Influenza and Other Respiratory Viruses, Infectious Diseases Department, National	8
 Institute of Health, Lisbon, Portugal ² Epidemiology Department, National Institute of Health, Lisbon, Portugal ³ COVID-19 Working Group, National Institute of Health, Oporto, Portugal ⁴ Occupational Health Department, National Institute of Health, Lisbon/Oporto, Portugal ⁵ Immunology laboratory for Infectious Diseases, Infectious Diseases Department, National Institute of Health, Lisbon, Portugal ⁶ Infectious Diseases Department, National Institute of Health, Lisbon, Portugal ⁷ Authors contributed equally to the study and manuscript writing * Correspondence: raquel.guiomar@insa.min-saude.pt; ana.carvalho@insa.min-saude.pt 	9 10 11 12 13 14 15 16 17
Abstract: Vaccination is considered the most important measure to control the COVID-19 pandemic. Extensive	18
follow-up studies with distinct vaccines and populations are able to promote robust and reliable data to better	19
understand the effectiveness of this pharmacologic strategy. In this sense, we present data regarding binding and neutralizing antibodies throughout time, from vaccinated and previously infected (PI) health care workers	20 21
(HCW) in Portugal. We analyzed serum samples of 132 HCW, vaccinated and with previous SARS-CoV-2 infec-	21
tion. Samples were collected before vaccination (baseline, M1), at second dose vaccine uptake (M2), and 25-70	23
days (M3) and 150-210 days (M4) after the second dose for vaccinated individuals. The IgG (anti-RBD/S) antibody	24
geometric mean titer found on vaccinated HCW at M2 (814.7 AU/ml; 95% CI 649.8-1021.5) were significantly	25
higher than those found on PI HCW at recruitment (M1) (252.6 AU/ml; 95% CI 108.7 - 587.1), and the neutralizing	26 27
antibodies (nAb) were similar between these groups, 93.2 UI/ml (95% CI 73.2- 118.5) vs. 84.1 UI/ml (95% CI 40.4- 155.9), respectively. We detected about 10-fold higher IgG (anti-RBD/S) antibodies titers in M3 when compared	27
with M2, with a slightly but significant decrease in titers from 36 days after the second dose vaccine uptake. The	29
increase of nAb titers were correlated with IgG (anti-RBD/S) antibodies titers, however, contrasting to IgG (anti-	30
RBD/S) antibodies titers, we did not detect a decrease in nAb titer from 36 days after a second vaccine dose uptake.	31
At M4, was observed a decrease of 8-fold in binding IgG (anti-RBD/S) and nAb. No significant differences in	32
antibody titers were observed by sex, age or chronic diseases. Our results suggest that IgG (anti-RBD/S) antibodies titers and nAb titers could be correlated, but ongoing follow up of the cohort, is required to better understand	33 34
this correlation, and the duration of the immune response.	35
Keywords: Covid-19; immunology; health care workers, neutralizing antibodies;	36
	37
	38
1. Introduction	39

Vaccination is an important public health measure to control the Coronavirus Disease 2019 (COVID-40 19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Substantial effort 41 has do ten This locaprint verd deviate dee at even a vertice of the predeceiving and the Whole of the local definition of the canonabetice. 42

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

anisms were used in vaccines development, among them, the novel technology of mRNA-based vac-43 cines [2], such as Comirnaty® and Spikevax® and the adenoviral vector vaccines as Vaxzevria®, and 44 COVID-19 Vaccine Janssen[®] which are being used in the vaccination program of Portugal, to date [3]. 45 In the actual pandemic context, given the record time from the research to the production and mass 46 application of vaccines, the follow-up of vaccinated people is essential to obtain data regarding anti-47 body response among different populations, under different epidemiological contexts [4]. In addition 48 to the vaccine-effectiveness estimates, studies on immunogenicity are important to monitor vaccine 49 performance. 50

The Spike protein (S) of SARS-CoV-2 is actually the target used in most vaccine development, since 51 the receptor-binding domain (RBD), in subunit S1 of this protein, is considered the main target to 52 binding and neutralizing antibodies [5]. Thus, it is expected that vaccinated people present anti-pro-53 tein S antibodies, while people with previous COVID-19 may present anti-protein S and anti-nucleo-54 protein antibodies [6].

Previous studies demonstrated high seroconversion (up to 90%) in both vaccinated and infected people, although high heterogeneity among individuals was observed [7–9], however, the duration of the adaptive immune response is not well established to date. Some studies have demonstrated antibodies persistence in previously infected individuals for, at least, 12 months after symptoms onset [7], and at least 6 months after the complete vaccination scheme in vaccinated individuals [10].

The correlation between binding and neutralizing antibodies titers and protection is not clear in infection by SARS-CoV-2, and a cut off to predict protection is not available. A meta-analysis study based on 7 different COVID-19 vaccines had evidenced a correlation between binding and neutralizing antibodies with protection against symptomatic COVID-19, indicating the use of antibodies tests to correlate protection against disease, but no threshold was established [11].

In order to clarify questions regarding heterogeneity of immune response among individuals, duration of the adaptive immune response, correlation among biding and neutralizing antibodies and protection, the future need of vaccines boosters, among others, it is essential to carry on studies based on real-life observation of different populations and on different vaccines. This is particularly true for serological response and vaccine effectiveness measured at same time. The answers to these questions are an important key to delineate the next strategies to control the COVID-19 pandemic. 71

In Portugal, the vaccination program against COVID-19 started in December 27, 2020. As in the ma-72 jority of European countries, the National Directorate of Health and the Ministry of Health defined a 73 strategy that prioritized front-line Health Care Workers (HCW) for vaccination, since they are essen-74 tial to maintain the health care units operational during the pandemic, but also because they are at 75 higher risk of SARS-CoV-2 infection, and given the closed contact between these professionals and 76 patients with comorbidities, with increased possibility of virus transmission to patients with high risk 77 for severe disease [12]. The first vaccines to be available in Portugal were Comirnaty® followed by 78 Spikevax® (both vaccines recommended to ≥12 years); Vaxzevria® (first recommended to individuals 79 aged less than 65 years and then changed into individuals aged 60 or more years) and COVID-19 80 Vaccine Janssen[®] (recommended to women aged \geq 50 years old or adults men) [3]. Following the na-81 tional vaccination guidelines, during the study period those people with previous infection were vac-82 cinated after 6 months from the laboratory diagnosis, with one dose of any vaccine [13]. 83

The National Institute of Health Dr. Ricardo Jorge (INSA) has approximately 500 HCW in its staff, into84which 81 were considered as front-line HCW to receive the vaccine against COVID-19 in the first phase85of the national vaccination program.86

Assuming the importance of specific SARS-CoV-2 antibodies as a proxy of the immune response to COVID-19 vaccines, HCW of INSA were followed-up for the first 6 months after the second vaccine dose uptake. In this study, we report findings regarding binding and neutralizing antibodies in vaccinated and previously infected HCW of INSA, in Portugal, from the baseline moment (recruitment or the first vaccine dose uptake) throughout, 6 months after the second vaccine dose uptake. 91

2. Materials and Methods

92

93

2.1. Design and participants

A prospective cohort study among INSA's staff was implemented to examine SARS-CoV-2 vaccine 94 effectiveness, including the serological component. 95

The INSA institutional vaccination campaign began on 12 January 2021. HCW (aged \geq 18 years old)

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

96

128

129

130 131

were invited to participate and were assigned into either the vaccinated cohort or the non-vaccinated 97 cohort at the beginning of the follow-up period. Individuals were asked to participate via institutional 98 email by the occupational medical service. 99 At the baseline, all participants filled-in a recruitment questionnaire were risk factors, symptoms and 100 vaccination data were collected. In addition, all participants were followed on a weekly basis, by fill-101 in an online questionnaire on SARS-CoV-2 exposure and infection symptoms. Nasopharyngeal/oro-102 pharyngeal swab was collected for SARS-CoV-2 detection by RT-PCR tests when reported suspected 103 signs and symptoms of COVID-19 on the weekly questionnaire or under the periodic testing screening 104 at INSA. 105 2.2. Inclusion criteria 106 All staff of INSA that consent to participate of our cohort study of vaccine effectiveness against 107 COVID-19 was included in this research project. 108 109 2.3. Exclusion criteria 110 The participants of our cohort study that did not received any dose of vaccine or that had not a previ-111 ous infection were excluded of this analysis. 112 113 2.4. Definitions 114We considered as vaccinated, individuals with more than 14 days after complete vaccination (receiv-115 ing all doses recommended in the product characteristics); and as partially vaccinated, individuals 116 with 14 days after receiving the first dose and until 14 days after receiving the second dose (in case of 117 2 doses). Additionally, as "previous infection" an individual who reported a positive RT-PCR test to 118 SARS-CoV-2 or had a positive RT-PCR test to SARS-CoV-2 and/or had anti-SARS-CoV-2 antibodies in 119 a serum sample taken in the recruitment at Moment 1(M1), before vaccine uptake. 120 121 2.5. Serological tests 122 Blood samples (3-5mL) were collected through venipuncture at baseline (M1) for all participants (in-123 cluding previously infected individuals), 30 days after first dose vaccine uptake (M2), 30 days after 124 second dose (M3) and at 6 months follow up (M4). After a centrifugation at 2500rpm for 15min serum 125 was obtained and conserved refrigerated (2 - 8°C) for a maximum of 7 days before laboratorial analysis 126 to detection of IgG antibodies and then, were stored frozen (-20°C) until the neutralizing antibodies 127

2.6. Determination of IgG antibodies

test was performed.

The determination of SARS-CoV-2 specific antibodies was done by a chemiluminescence enzyme im-132 munoassay used for quantitative detection of Anti- receptor-binding domain (RBD) from spike protein 133 (S) antibodies (IgG anti-RBD/S) against SARS-CoV-2. Assays were performed in serum samples by the 134 SARS-CoV-2 IgG II Quant assay (Abbott Diagnostics, IL, USA). Sera samples were considered positive 135 when presented results >50 AU/mL. The tests were performed according to the manufacturer's in-136 structions. 137

The determination of IgG(anti-RBD/S) was performed at baseline, before first vaccine dose uptake 138 (M1), before second vaccine dose uptake (M2), 25 to 70 days after second vaccine dose or completion 139

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

of vaccination scheme (M3), and at 150 and 210 days after second vaccine dose or completion of vaccination scheme (M4). 141

142

157

158

2.7. Determination of neutralizing antibodies

143

The determination of neutralizing antibodies was performed at M2, M3 and M4 to vaccinated partici-144pants and at M1 to participants that had previous infection, using the commercial Enzyme-Linked 145 Immunosorbent Assay (ELISA) kit TECO® SARS-CoV-2 Neutralization Antibody Assay (TECOmedi-146 cal AG, Sissach, Switzerland), in the fully automated ELISA System DYNEX DS2®(Chantilly, VA, 147 USA). The test has the principle of competitive binding, based on protein-protein interaction from the 148 virus spike (S) protein (receptor binding domain - RBD) and the host cell receptor protein (angiotensin-149 converting enzyme 2 -ACE2). The test was performed according to the manufacturer's instructions. 150 The interpretation of the results was performed by the DYNEX DS2® system, and the results in IU/mL 151 was obtained based on the optic density (OD) of each sample. The limit of interpretation of the equip-152 ment is in the interval between 5 IU/mL and 500 IU/mL. Those samples that presented a value >500 153 IU/mL to nAb were re- analyzed in dilutions of 5X or 10X, to obtain the most robust result possible to 154 perform the statistical correlation among binding and neutralizing antibodies. The cutoff to determine 155 the presence of neutralizing antibodies was stablished as >20 IU/mL. 156

2.8. Statistical analyses

Demographic, social and health characteristics of vaccinated (including partially vaccinated) individuals at baseline are described as relative frequencies for categorical and means and standard deviations for numerical variables.

For vaccinated, partially vaccinated and individuals with previous infection of COVID-19 data on the 162 quantification of IgG (anti-RBD/S) and nAb antibody response activity was represented as an esti-163 mated geometric mean (GM) with 95% confidence interval (95% CI). The Wilcoxon's rank sum test 164 was applied to detect statistical differences for the IgG (anti-RBD/S) titers (GMT) at different moments. 165 Between the 1st dose (20-30 days after vaccination, M2) and 2nd vaccine dose or completion of vac-166 cination scheme (25-70 days after vaccination, M3), and between these two moments and 5 to 7 months 167 after vaccination (150 to 210 days after 2nd dose or 1st dose in one uptake vaccine scheme, M4). Given 168 the difference of elapsed time since completion of vaccination scheme and blood sample collection at 169 the M3, we also tested the differenced in GMT for two moments after vaccination scheme completion 170 (25-35 days vs. 36-70 days). Spearman's coefficient and p-value were calculated to evaluate the corre-171 lation between IgG (anti-RBD/S) and neutralizing response activity (nAb). A linear regression was 172 performed on log-transformed IgG (anti-RBD/S) titers at the M3 (25 to 70 days after 2nd vaccine dose) 173 and at the M4 (150 to 210 days after 2nd vaccine dose) to determine the association to sex, age groups 174 (20-39, 40-70 years) or chronic disease (at least one chronic disease/no disease) for vaccinated individ-175 uals. Statistical significance was defined as p < 0.05. 176

All statistical analyses were performed using Stata software, version 15 (StataCorp.2017. Stata Statistical Software). 177

2.9. Ethical considerations

The study complied with legal and ethical requirements. The study protocol was approved by the181National Institute of Health Doctor Ricardo Jorge Health Ethics Committee. All participants provided182written informed consent for collection of data regarding demographic, social, and health information,183blood samples and nasopharyngeal/oropharyngeal swabs.184

185

179

180

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

3. Results

187 188

Out of 212 workers that integrated the INSA cohort at 15 June 2021, 132 were included in this study: 189 114 from the vaccinated and partially vaccinated group and 18 individuals with previous infection: 190 with a RT-PCR positive test (n=14) or with a positive serological analysis with the detection of antibodies against SARS-CoV-2 in serum sample (n=4). These 4 individuals were therefore unaware of having been expose to the SARS-CoV-2. 193

From the vaccinated group, 84 were vaccinated against SARS-CoV-2, and 30 were partially vaccinated 194 (Table 1). Vaccinated participants had mostly taken the Comirnaty® vaccine (96.4%), the others with 195 COVID-19 Vaccine Janssen® (2.4%) and the Vaxzevria® (1.2%). Of the partially vaccinated individu-196 als, 66.7% had taken the Comirnaty[®], 20% the Vaxzevria[®] and 13.3% the Spikevax. In both groups, 197 the majority were women (81% and 90%, respectively), and the mean of ages was lower for the vac-198 cinated group (\bar{x} =44 (23-67) versus \bar{x} =57(46-69)). Within the vaccinated group, over 68% reported to 199 work in laboratory, whereas over 81% of the partially vaccinated group reported to work in services 200 that did not required interaction with the public. Regarding smoking habits, 11% of the fully vac-201 cinated individuals and 23% of the partially vaccinated reported to be smokers. Little less than half of 202 vaccinated (48.7%) and 68.4% of the partially vaccinated participants reported at least one chronic 203 disease. In both groups, over 70% of participants reported to have uptake the influenza vaccine in the 204 previous season. 205

medRxiv preprint doi: https://doi.org/10.1101/2021.12.10.21267607; this version posted December 13, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

	Vaccinated		Partially v	
			(1 do	
	n	%	n	%
Total	84		30	
Sex				
Female	68	81.0	27	90.0
Male	16	19.0	3	10.0
Age, mean [range]	(x=44[23-67])		(x=57[46-69])	
Age groups (n)	(83)		(30)	
20 to 49 years	44	53.0	5	16.7
50 to 70 years	39	47.0	25	83.3
Work functions	(79)		(26)	
Without public contact	13	16.5	21	80.8
Public contact	12	15.2	4	15.4
Laboratory	54	68.4	1	3.8
Smoking	(82)		(30)	
Never smoked	54	65.9	16	53.3
Smoker	9	11.0	7	23.3
Former smoker	19	23.2	7	23.3
Chronic disease (n)	(70)		(19)	
No disease	38	54.3	6	31.6
1+ disease	32	45.7	13	68.4
Flu vaccine season	(81)		(28)	
2020/2021 (n)				
No	24	29.3	5	17.9
Yes	58	70.7	23	82.1


Table 1 Vaccinated and partially vaccinated participants' sociodemographic, work, and health characteristics.

207

At M1, the IgG (anti-RBD/S) titers were higher for individuals with previous SARS-CoV-2 infec-209 tion (Erro! A origem da referência não foi encontrada.). Information about the date of the positive 210 PCR test was only available for 11 of the 18 individuals with previous infection. Individuals that have 211 had previous infection in the last 90 days presented a higher GM (GM=627.5AU/mL; CI: 168.3-2338.8) 212 than those individuals that had been infected prior to 90 days (GM=408.5 AU/mL; CI: 184.2-905.9). 213

214

medRxiv preprint doi: https://doi.org/10.1101/2021.12.10.21267607; this version posted December 13, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .



plots for individuals with previous infection and vaccinated individuals without previous infection for the four different 217

moments of observation. 218

219

235

Table 2 displays the GM for IgG (anti-RBD/S) titers for different groups and moments. The concentra-220 tion of IgG (anti-RBD/S) was significantly higher (GM= 814.7 AU/mL; CI: 649.8-1021.5) for the vac-221 cinated individuals at M2, when compared to the values observed at M1 for the individuals previously 222 infected (GM= 252.6 AU/mL; CI:108.7-587.1) (p<0.001). 223

For vaccinated participants, antibodies titers were significantly higher after the second vaccine dose, 224 with an increase of about 10-fold from M2 to M3 in the IgG (anti-RBD/S) antibodies titers 225 (GM=8803.8AU/mL, 95 % CI: 7529.5-10293.7) (p<0.0001). For the M3, serum samples were drawn at 226 several distinct times, comprising a broad range of days between sample collection and second dose 227 uptake. Vaccinated individuals whose blood samples were drawn between 25 and 35 days after the 228 second dose presented a higher GM of IgG (anti-RBD/S) concentration (GM=10773.0AU/mL, CI:8910.2-229 13025.3), compared to those whose sample collection took place after the 35 until 70 days 230 (6912.1AU/mL, CI:5447.3- 8770.8) (p<0.05). Even though the concentration of IgG (anti-RBD/S) titers 231 decreased at M4 (GM= 1070.4 AU/mL; CI: 922.5-1241.9) and was significantly lower when compared 232 to the values observed at M3 (p<0.001). Antibody titers at M4 were still significantly higher than ob-233 served for the vaccinated individuals at M2, after the 1st vaccine dose (p<0.05). 234

Table 2. Geometric Mean (GM) of SARS-CoV-2 IgG (anti-RBD/S) concentration titers at four different moments for the 236 full-vaccinated, partially vaccinated participants and at moment of recruitment for individuals with previous infection. 237

Groups	M1 [CI95%] (n)	M2 (Vaccinated	M3 (Vaccinated)			M4 (Vaccinated)
		and partial) [CI95%] (n)	Total [CI95%] (n)	25-35 days [CI95%] (n)	36-70 days [CI95%] (n)	150-210 days [CI95%] (n)
Vaccinated & Partially vaccinated*	2.5 [1.9-3.4] (n=96)	814.7 [649.8- 1021.5] (n=63)	8803.8 [7529.5 10293.7] (n=81)	10409.0 [8507.9 12734.7] (n=49)	6812.2 [5400.7 8592.6] (n=32)	1070.4 [922.5- 1241.9] (n=72)

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Previous						
rievious	252.6 [108.7					
infection	202.0 [100.7					
	587.1]	-	-	-	-	_
(n=17)						

Linear regression was performed on log-transformed IgG (anti-RBD/S) titers at the M3 and M4 to determine the association to sex, age groups or chronic disease for vaccinated individuals (Table 3). No statistical differences (p>0.05) in the GM of IgG (anti-RBD/S) concentration were observed between men or women, between individuals in the two age groups or between individuals without or with at least one chronic disease at each of the observed moments. 243

Table 3. Regression on log-transformed SARS-CoV-2 IgG (anti-RBD/S) titers at the M3 (25-70 days after 2nd dose) and245M4(150-210 days after 2nd dose) for full-vaccinated individuals.246

		M3			M4	
Variable	Odds	95% CI	Р	Odds	95% CI	Р
	Ratio			Ratio		
Sex	(n=87)			(n=72)		
Female	*			*		
Male	0.83	0.56-1.2	0.358	0.79	0.51-1.2	0.298
Age	(n=86)			(n=72)		
20-49	*			*		
50-70 years	1.08	0.79-1.48	0.626	0.86	0.60-1.2	0.415
Chronic disease	(n=71)			(n=61)		
No disease	*			*		
1+ disease	1.19	0.84-1.69	0.310	0.95	0.70-1.3	0.776

*Constant

247

238

244

248

To explore the humoral immune response generated after SARS-CoV-2 infection, the neutralizing an-
tibody response (nAb) was evaluated for individuals with previous infection at recruitment (M1), and
for vaccinated individuals at M2, M3 and M4 (Figure 2).249250251

medRxiv preprint doi: https://doi.org/10.1101/2021.12.10.21267607; this version posted December 13, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .




Figure 2. Concentration of neutralizing antibodies (nAb) titers reported in the box-whisker plots for individuals with 254 previous infection and vaccinated individuals without previous infection for the four different moments of observation. 255

253

Table 4 presents the geometric mean of nAb activity in serum samples of participants with previous 256 infection at M1, and for vaccinated and partially vaccinated individuals at M2 and M3. The GM of 257 nAb in previously infected individuals at M1 (GM=84.1 mL; CI: 40.4-155.9) was not different from that 258 observed for vaccinated individuals at M2 (GM=93.2IU/mL; CI: 73.2-118.5) (p=0.645). On the other 259 hand, when compared with M2, a significant increase of nAb titer was observed in the M3 for vac-260 cinated individuals (GM=1267.3 IU/mL; CI: 1060.6-1514.4) (p<0.001). Statistical significant differences 261 were also observed in the nAb concentrations between 25 to 35 days (GM=1551.9 IU/mL; CI: 1261.4-262 1909.5) and 36 and 70 days (GM=935.2 IU/mL; CI: 691.6-1264.7) after the second vaccine dose or com-263 pletion of the vaccination scheme (p<0.05). Even though a decrease of nAb concentrations titters in the 264 last moment of observation (M4, GM=165.8 IU/mL; CI: 128.4-214.2), the titers were still significantly 265 higher than those observed after the first vaccine dose (p<0.05). 266 267

Table 4. Geometric Mean (GM) of neutralizing antibodies (nAb) titers at four different moments for the full-vaccinated, 268 partially vaccinated participants and at moment of recruitment for individuals with previous infection 269

Groups	M1 [CI95%] (n)	M2 (Vaccinated		M4 (Vaccinated)		
		and partial) [CI95%] (n)	Total [CI95%] (n)	25-35 days [CI95%] (n)	36-70 days [CI95%] (n)	150-210 days [CI95%] (n)
Vaccinated & Partially vaccinated*	-	93.2 [73.2- 118.5] (n=84)	1267.3 [1060.6 1514.4] (n=80)	1551.9 [1261.4- 1909.5] (n=48)	935.2 [691.6 1264.7] (n=32)	165.8 [128.4- 214.2] (n=68)
Previous infection (n=14)	84.1 [40.4- 155.9]	_	_	_	_	-

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

High statistically significant correlations were observed between IgG (anti-RBD/S) and nAb titers, at 271 all observational moments. After the first vaccine dose (M2) IgG (anti-RBD/S) titers correlated highly 272 with nAb titers (Spearman's $\varrho = 0.79$, p<0.001). Similar higher correlations were observed at M3 273 (Spearman's $\varrho = 0.86$, p<0.001), either 25 to 35 days (Spearman's $\varrho = 0.81$, p<0.001) or 36 to 70 days 274 after completion of vaccination scheme (Spearman's $\varrho = 0.87$, p<0.001). Finally, at M4, a significant 275 correlation, was observed between IgG (anti-RBD/S) and nAb titers (Spearman's $\varrho = 0.70$, p<0.001). 276

4. Discussion

278

277

270

In this work, we accessed the preliminary data regarding binding and neutralizing antibodies in 279 HCW from National Public Health Institute, Portugal, from the baseline, before first vaccine dose uptake, until 150-210 days (5-7 months) after the second vaccine dose. We demonstrated that the first 281 vaccine dose elicited an immunological response although a second dose was essential to promote a 282 boost in binding and neutralizing antibodies SARS-CoV-2. IgG (anti-RBD/S) were highly correlated 283 with neutralizing antibodies, being higher in the first 70 days (10 weeks), keeping however a good 284 correlation after completion of the vaccination scheme. 285

The IgG (anti-RBD/S) titer was significantly higher in vaccinated individuals, after one or two vac-286 cine doses, compared with baseline values of individuals that had developed an immunity response 287 after a previous SARS-CoV-2 infection. The GM of IgG (anti-RBD/S), after one vaccine dose, from 288 vaccinated individuals was significantly higher (p<0.001) than GM found at recruitment for individ-289 uals that had a previous infection. This data is in accordance with the previously reported from a 290 cohort of HCW from an academic medical center in Southern California [14] and with the Portuguese 291 national serological survey performed in February-March 2020 [15]. However, we have to take in 292 consideration that the elapsed time between infection and the recruitment to this study had a great 293 variation among individuals. Due to the lower sample size between these groups, it is not possible 294 to perform a robust comparative analysis in the group of previous SARS-CoV-2 infection. 295

The marked increase of the IgG (anti-RBD/S) after the second dose, found in this study was compat-296 ible with the observed in previous studies [6,8,10,14], and in trials studies [16]. It is important to high-297 light that after the second dose we found a significant decrease for IgG (anti-RBD/S) between indi-298 viduals that had a serum analysis from 25 to 35 days and those that had a serum analysis from 36 to 299 70 days, after the second dose. This decrease was expected given that after the second dose there is 300 a high stimulation of immune system, with high production of antibodies, however it is not expected 301 that the IgG titers be kept at the maximum for a long time, and though a decreasing to basal titers of 302 memory is generally observed [17,18]. This decrease was also found in other studies [10,19]. In this 303 sense, is important to keep the follow up of the cohort studies in order to clear for how long the IgG 304 titers remains and to try to correlate this data with nAb, and to establish a cut off that could predict 305 protection against SARS-CoV-2 infection. Other studies in health care workers showed that the effi-306 cient immunological response to COVID-19 vaccines is associated with a reduction of new COVID-307 19 cases among those who received two doses of the vaccine, even when a surge of the B.1.1.7 variant 308 was noted in up to 80% of cases. The effective vaccination among health care workers provides a 309 safe environment, even in the presence of a high rate of SARS-CoV-2 infection in the community. 310 Although there is a good effectiveness for COVID-19 vaccines, is recognized a decrease in vaccine 311 effectiveness with time [20]. A study from England, found high levels of vaccine effectiveness against 312 symptomatic disease after two doses, even when a new variant Delta was circulating [21]. New 313 variants can also pose a challenge to COVID-19 vaccine effectiveness that expresses the perfusion 314 stabilized full spike glycoprotein (S) of the original SARS-CoV-2 isolate Wuhan-Hu-1, but recent 315 studies have already highlighted that variants of concern [22], Alpha (B.1.1.7 variant), Beta variant 316 first identified in South Africa (B.1.351 lineage), and Gamma variant first identified in Brazil (P.1 317 lineage) remained susceptible to Comirnaty® vaccine elicited serum neutralization, although at a 318 reduced level for the B.1.351 variant [23,24]. For the Delta variant, predominant in Portugal since 319 mid-June 2021 [25], studies on cross-reactivity of monoclonal antibodies to pre-existing SARS-CoV-320 2 strains, showed that vaccination of previously infected individuals is likely to be protective against 321 a large array of circulating viral strains, including the Delta variant. In the same way, two-dose reg-322

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

imen generated high sera-neutralization levels against the Alpha, Beta and Delta variants in individuals sampled at week 8 to week 16 after vaccination [26], being the levels of neutralizing antibodies highly predictive of immune protection from symptomatic SARS-CoV-2 infection [27]. A study at national level estimated high mRNA VE for the prevention of COVID-19-related hospitalizations and deaths (in \geq 65 years, full vaccinated) with any evidence of VE reduction in the 3 months after the second dose uptake, during the period of Delta variant circulation [28], consistent with the high titers for binding and neutralizing antibodies detected after complete vaccination. 329

In opposite to other studies such as one performed in UK, where people older than 50 years old 330 presented a weaker serological response in relation to those younger than 50 years old [29], in our 331 study we did not identify any difference between age, sex, or the presence of one or more chronic 332 diseases. This fact can be due to the limited sample size of our study, which do not allow a more 333 robust analysis. 334

Our study has some limitations, the cohort includes only active healthy workers, without severe 335 comorbidities, and all participants are under 70 years old, with over representation of the female 336 population. The occupational risk is reduced, although the majority of the participants manipulate 337 SARS-CoV-2 positive samples, strict guidelines to use individual protective equipment limit the oc-338 cupational risk exposure being reduced compared to medical personnel with close contact with pa-339 tients. The heterogeneity in the reference units to quantify the detected antibodies posed a difficulty 340 to compare our data with other studies. Few studies used the same units that we used in this study. 341 This point was already highlighted by Earle et al., [11] that suggested the use of the WHO Interna-342 tional Standard (NIBSC 20/136) to express neutralizing antibodies titers in IU/mL and binding anti-343 bodies titers in BAU/mL to be possible to compare data among different studies using serology as-344 says, in the context of COVID-19 pandemic. Given the importance to compare different vaccines 345 among different populations to help to design new strategies to battle the pandemic, this point is 346 crucial to a better comprehension of data obtained around the world. We didn't explore the antibody 347 titers for variants of concern, and a decrease of antibody titers could be expected. The cellular im-348 munity and other immunological mechanisms weren't explored during the study. 349

In our study, we found a high correlation between biding and neutralizing antibodies after the first 350 dose and similar results have been previously reported by other authors [30,31]. It was reported that 351 nAb remain relatively stable for several months after infection, but there is a lack of information on 352 for how long time it persists [31]. The slower decrease in nAb after the second vaccine dose uptake, 353 could support a robust and long persistence of nAB after full vaccination [20,31,32]. A recent study 354 reported a good correlation between binding and neutralizing antibodies levels and protection 355 against symptomatic infection [33]. Although we observed a decrease in nAb titers levels about 6 356 months after vaccination, it was high far away from the minimum level reported by Feng et al. asso-357 ciated with 80%VE against symptomatic infection, with majority Alpha variant (26 IU/mL for pseu-358 dovirus neutralization). In our study, we were not able to predict the loss of protection due to the 359 decrease of nAb at 5-7 months after full vaccination neither to confirm that the nAb levels found at 360 this moment are considered a robust immune response. In this sense, we recommend caution in the 361 interpretation of the decrease of the levels of biding and neutralizing antibodies, especially in face to 362 the new variants challenge. 363

The preliminary data obtained from our cohort study demonstrate the importance to keep the follow 364 up of the individuals in order to better understand the behavior of immune response to the COVID-365 19 vaccines, and to try to establish a threshold that could predicts protection against the SARS-CoV-366 2 infection. Serological studies precluding the waning of antibody levels with time must be inte-367 grated in the vaccine effectiveness studies to better clear questions about the duration of immune 368 protection and vaccine effectiveness. The data on waning immunity and vaccine effectiveness con-369 stitute important facts for health decision makers, to implement measures to reduced severe disease, 370 mortality and transmission that could comprises non-pharmaceutical measures and/or additional 371 booster vaccine doses. 372

medRxiv preprint doi: https://doi.org/10.1101/2021.12.10.21267607; this version posted December 13, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Author Contributions: Conceptualization, R.G. and A.M.; methodology, A.M.M.; I.C.; R.M.; A.S.S.; C.R.; C.S.; 374 J.A.; F.G.; A.S.G.; software, A.J.C.; I.K.; writing-original draft preparation, R.G; A.J.C.; A.M.M.; writing-re-375 view and editing, R.G.; A.J.C.; A.M.M.; I.C.; R.M.; A.P.R.; I.K.; A.S.S.; C.R.; C.S.; J.A.; F.G.; A.S.G.; A.M.. All 376 authors have read and agreed to the published version of the manuscript." 377 Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration 378 of Helsinki, and approved by the Ethics Committee of National Institute of Health Doutor Ricardo Jorge. 379 Informed Consent Statement: Informed consent was obtained from all subjects involved in the study. 380 381 Acknowledgments: We would like to acknowledge all the participants from the staff of the National Institute 382 of Health for the availability to participate in the present study and to donate blood samples for the evaluation 383 of the humoral immunity response after vaccination. 384 We acknowledge the colleagues that contributed to the support of the present study: Paula Braz from the De-385 partment of Epidemiology of INSA; Camila Henriques, Carla Manita, Fátima Martins, João Santos, Jorge Ma-386 chado and Sofia Soeiro from the Infectious Diseases Department, INSA. We acknowledge the colleagues from 387 Management and Laboratory Support Unit. 388 Conflicts of Interest: The authors declare no conflict of interest. 389 References 390 1. WHO Evaluation Of COVID-19 Vaccine Effectiveness. 2021, 70. 391 2. Forni, G.; Mantovani, A.; Forni, G.; Mantovani, A.; Moretta, L.; Rappuoli, R.; Rezza, G.; Bagnasco, A.; 392 Barsacchi, G.; Bussolati, G.; et al. COVID-19 vaccines: where we stand and challenges ahead. Cell Death 393 Differ. 2021, 28, 626-639, doi:10.1038/s41418-020-00720-9. 394 3. INFARMED INFARMED COVID-19 -VACINAS APROVADAS (quadro resumo) 2021. 395 4. Carrillo, J.; Izquierdo-Useros, N.; Ávila-Nieto, C.; Pradenas, E.; Clotet, B.; Blanco, J. Humoral immune 396 responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective 397 immunity. Biochem. Biophys. Res. Commun. 2021, 538, 187–191, doi:10.1016/j.bbrc.2020.10.108. 398 5. Lombardi, A.; Bozzi, G.; Ungaro, R.; Villa, S.; Castelli, V.; Mangioni, D.; Muscatello, A.; Gori, A.; Bandera, 399 A. Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: 400 Preliminary Results. Front. Immunol. 2021, 12, 1-11, doi:10.3389/fimmu.2021.657711. 401 6. Gobbi, F.; Buonfrate, D.; Moro, L.; Rodari, P.; Piubelli, C.; Caldrer, S.; Riccetti, S.; Sinigaglia, A.; Barzon, 402 L. Antibody response to the bnt162b2 mrna covid-19 vaccine in subjects with prior sars-cov-2 infection. 403 Viruses 2021, 13, 1-10, doi:10.3390/v13030422. 404 Dobaño, C.; Ramírez-Morros, A.; Alonso, S.; Vidal-Alaball, J.; Ruiz-Olalla, G.; Vidal, M.; Rubio, R.; 7. 405 Cascant, E.; Parras, D.; Rodrigo Melero, N.; et al. Persistence and baseline determinants of seropositivity 406 and reinfection rates in health care workers up to 12.5 months after COVID-19. BMC Med. 2021, 19, 1-6, 407 doi:10.1186/s12916-021-02032-2. 408 8. Callegaro, A.; Borleri, D.; Farina, C.; Napolitano, G.; Valenti, D.; Rizzi, M.; Maggiolo, F. Antibody 409 response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 410 infection. J. Med. Virol. 2021, 93, 4612-4615, doi:10.1002/jmv.26982. 411 9. Manisty, C.; Otter, A.D.; Treibel, T.A.; McKnight, Á.; Altmann, D.M.; Brooks, T.; Noursadeghi, M.; Boyton, 412 R.J.; Semper, A.; Moon, J.C.; et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-413 infected individuals. Lancet 2021, 397, 1057-1058, doi:10.1016/S0140-6736(21)00501-8. 414 10.

10.Nicole Doria-Rose, P.D.; (NIAID); Mehul S. Suthar, P.D. Antibody Persistence through 6 Months after the415Second Dose of mRNA-1273 Vaccine for Covid-19. *new Engl. J. o f Med.* 2021, 384.416

Earle, K.A.; Ambrosino, D.M.; Fiore-Gartland, A.; Goldblatt, D.; Gilbert, P.B.; Siber, G.R.; Dull, P.; Plotkin,
 S.A. Evidence for antibody as a protective correlate for COVID-19 vaccines. *Vaccine* 2021, 39, 4423–4428,
 doi:10.1016/j.vaccine.2021.05.063.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.10.21267607; this version posted December 13, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

12.	Rudberg, A.S.; Havervall, S.; Månberg, A.; Jernbom Falk, A.; Aguilera, K.; Ng, H.; Gabrielsson, L.;	420
	Salomonsson, A.C.; Hanke, L.; Murrell, B.; et al. SARS-CoV-2 exposure, symptoms and seroprevalence in	421
	healthcare workers in Sweden. Nat. Commun. 2020, 11, 1–8, doi:10.1038/s41467-020-18848-0.	422
13.	Direção-Geral da Saúde Norma nº 002/2021 de 30/01/2021 atualizada a 21/04/2021; 2021;	423
14.	Ebinger, J.E.; Fert-Bober, J.; Printsev, I.; Wu, M.; Sun, N.; Prostko, J.C.; Frias, E.C.; Stewart, J.L.; Van Eyk,	424
	J.E.; Braun, J.G.; et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously	425
	infected with SARS-CoV-2. Nat. Med. 2021, 27, 981-984, doi:10.1038/s41591-021-01325-6.	426
15.	et. al. Ana Paula Rodrigues, Ana Cristina Garcia Inquérito Serológico Nacional Relatório de apresentação.	427
	2021 , <i>19</i> .	428
16.	Walsh, E.E.; Frenck, R.W.; Falsey, A.R.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Neuzil, K.;	429
	Mulligan, M.J.; Bailey, R.; et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine	430
	Candidates. N. Engl. J. Med. 2020, 383, 2439–2450, doi:10.1056/nejmoa2027906.	431
17.	Sethuraman, N.; Jeremiah, S.S.; Ryo, A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA - J. Am. Med.	432
	Assoc. 2020 , 323, 2249–2251, doi:10.1001/jama.2020.8259.	433
18.	Azkur, A.K.; Akdis, M.; Azkur, D.; Sokolowska, M.; van de Veen, W.; Brüggen, M.C.; O'Mahony, L.; Gao,	434
	Y.; Nadeau, K.; Akdis, C.A. Immune response to SARS-CoV-2 and mechanisms of immunopathological	435
	changes in COVID-19. Allergy Eur. J. Allergy Clin. Immunol. 2020 , 75, 1564–1581, doi:10.1111/all.14364.	436
19.	Wisnewski, A. V.; Luna, J.C.; Redlich, C.A.; Campillo Luna, J.; Redlich, C.A. Human IgG and IgA	437
	responses to COVID-19 mRNA vaccines. PLoS One 2021, 16, e0249499, doi:10.1371/journal.pone.0249499.	438
20.	Pilishvili, T.; Gierke, R.; Fleming-Dutra, K.E.; Farrar, J.L.; Mohr, N.M.; Talan, D.A.; Krishnadasan, A.;	439
	Harland, K.K.; Smithline, H.A.; Hou, P.C.; et al. Effectiveness of mRNA Covid-19 Vaccine among U.S.	440
	Health Care Personnel. N. Engl. J. Med. 2021 , 1–13, doi:10.1056/NEJMoa2106599.	441
21.	Lopez Bernal, J.; Andrews, N.; Gower, C.; Gallagher, E.; Simmons, R.; Thelwall, S.; Stowe, J.; Tessier, E.;	442
	Groves, N.; Dabrera, G.; et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N.	443
	<i>Engl. J. Med.</i> 2021 , 385, 585–594, doi:10.1056/nejmoa2108891.	444
22.	ECDC SARS-CoV-2 variants of concern as of 23 September 2021. ECDC 2021.	445
23.	Yang Liu, P.D.; Jianying Liu, P.D.; Hongjie Xia, P.D.; Xianwen Zhang, B.S.; Camila R. Fontes-Garfias, P.D.;	446
	Branch, U. of T.M.; Galveston, T.X.; Kena A. Swanson, P.D.; Hui Cai, P.D.; Ritu Sarkar, M.A.; et al.	447
	Neutralizing Activity of BNT162b2-Elicited Serum To. new Engl. J. o f Med. 2020, 69, 2016–2017.	448
24.	Yang Liu, P.D.; Jianying Liu, P.D.; Hongjie Xia, P.D.; Xianwen Zhang, B.S.; Jing Zou, P.D.; Camila R.	449
	Fontes-Garfias, P.D.; Scott C. Weaver, P.D.; Branch, U. of T.M.; Galveston, T.X.; Kena A. Swanson, P.D.;	450
	et al. BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. new Engl. J. o f Med.	451
	2021 , 385.	452
25.	Instituto Nacional de Saúde Doutor Ricardo Jorge, I.P. (INSA) Diversidade genética do novo coronavírus	453
	SARS-CoV-2 (COVID-19) em Portugal. 2021 , 2, 3.	454
26.	Planas, D.; Veyer, D.; Baidaliuk, A.; Staropoli, I.; Guivel-Benhassine, F.; Rajah, M.M.; Planchais, C.; Porrot,	455
_0.	F.; Robillard, N.; Puech, J.; et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody	456
	neutralization. <i>Nature</i> 2021 , <i>596</i> , 276–280, doi:10.1038/s41586-021-03777-9.	457
27.	Khoury, D.S.S.; Cromer, D.; Reynaldi, A.; Schlub, T.E.E.; Wheatley, A.K.K.; Juno, J.A.A.; Subbarao, K.;	458
	Knoury, D.S.S., Croner, D., Reynaud, A., Schub, T.E.L., Wheatey, A.K.K., Juno, J.A.A., Subbarao, K., Kent, S.J.J.; Triccas, J.A.A.; Davenport, M.P.P. Neutralizing antibody levels are highly predictive of	459
	immune protection from symptomatic SARS-CoV-2 infection. <i>Nat. Med.</i> 2021 , <i>27</i> , 1205–1211,	460
	doi:10.1038/s41591-021-01377-8.	400 461
28.	Nunes, B.; Rodrigues, A.P.; Kislaya, I.; Cruz, C.; Peralta-santos, A.; Lima, J.; Leite, P.P.; Sequeira, D.; Dias,	461
<u> </u>	, = ., realing aco, r in ., rading a, in Crail, Ch r crain barroo, rin Linna, j., Lenc, r in ., Dequera, D., Diab,	104

C.M.; Machado, A.; et al. mRNA vaccine effectiveness against COVID-19-related hospitalisations and 463

medRxiv preprint doi: https://doi.org/10.1101/2021.12.10.21267607; this version posted December 13, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

deaths in older adults : a cohort study based on data linkage of national health registries in Portugal, 464 February to August 2021. Eurosurveillance 2021, 26, 1-7, doi:10.2807/1560-7917.ES.2021.26.38.2100833. 465 29. Maria Prendecki, C.C.; Jonathan Brown, A.C.; Sarah Gleeson, M.G.; Paul Randell, A.D.P.; Liz Lightstone, 466 X.-N.X.; Wendy Barclay, S.P.M.; Peter Kelleher, M.W.; Prendecki, M.; Clarke, C.; Brown, J.; et al. Effect of 467 previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet 468 2021, 397, 1178-1181, doi:10.1016/S0140-6736(21)00502-X. 469 30. Demonbreun, A.R.; Sancilio, A.; Velez, M.P.; Ryan, D.T.; Saber, R.; Vaught, L.A.; Reiser, N.L.; Hsieh, R.R.; 470 D'Aquila, R.T.; Mustanski, B.; et al. Comparison of IgG and neutralizing antibody responses after one or 471 two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals. 472 EClinicalMedicine 2021, 38, 101018, doi:10.1016/j.eclinm.2021.101018. 473 31. Wajnberg, A.; Amanat, F.; Firpo, A.; Altman, D.R.; Bailey, M.J.; Mansour, M.; McMahon, M.; Meade, P.; 474 Mendu, D.R.; Muellers, K.; et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for 475 months. Science (80-.). 2020, 370, 1227-1230, doi:10.1126/science.abd7728. 476 32. Saad-roy, C.M.; Wagner, C.E.; Baker, R.E.; Morris, S.E.; Farrar, J.; Graham, A.L.; Levin, S.A.; Mina, M.J.; 477 Metcalf, C.J.E.; Grenfell, B.T. Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the 478next 5 years. Science (80-.). 2020, 818, 811-818. 479 Feng, S.; Phillips, D.J.J.; White, T.; Sayal, H.; Aley, P.K.K.; Bibi, S.; Dold, C.; Fuskova, M.; Gilbert, S.C.C.; 33. 480 Hirsch, I.; et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. 481 Nat. Med. 2021, doi:10.1038/s41591-021-01540-1. 482